Bristows Science Series

ADCs and radiopharmaceuticals - Wednesday 18 September 2024

Antibody-drug conjugates (ADCs) are revolutionising targeted therapy, particular for cancer, by harnessing the specificity of antibodies to deliver drugs directly to target cells. There is also currently a lot of attention on radiopharmaceuticals, which pair radioactive particles with antibodies or other targeted carrier molecules and have uses in diagnostic imaging as well as therapeutics.

In this session, Bristows will explore the science behind ADCs and radiopharmaceuticals, and examine the legal considerations relevant to these technologies.

Oncolytic viruses and cancer vaccines - Wednesday 2 October 2024

Oncolytic viruses and cancer vaccines are emerging as promising treatments in oncology. Oncolytic viruses selectively infect and destroy cancer cells, while therapeutic cancer vaccines stimulate the adaptative immune system against specific malignant cells so the immune system can destroy them. There is growing interest in their potential to complement traditional therapies like surgery, chemotherapy, and radiation.

In this session, Bristows will delve into the science behind oncolytic viruses and therapeutic cancer vaccines, exploring their mechanisms and applications, along with some legal considerations relevant to these technologies.